What Astronomers Just Discovered Between Galaxies Changes Everything
For decades, scientists have known that a massive chunk of the universe's ordinary matter was missing. Not dark matter, the elusive substance that doesn't interact with light, but regular, everyday matter made of atoms.
And now, thanks to a brilliant use of cosmic radio signals, that mystery may finally be solved.
In a new study published in Nature Astronomy, astronomers used fast radio bursts (FRBs)—brief, millisecond-long blasts of energy from deep space—to detect where all that missing matter was hiding: in the vast stretches between galaxies, known as the intergalactic medium.
These FRBs are powerful. Though short-lived, they emit as much energy in one burst as the sun does in 30 years. When they pass through space, they act like cosmic flashlights, lighting up the otherwise invisible gas that floats between galaxies.
The team measured how the light from 69 FRBs slowed as it moved through this matter, allowing them to "weigh" the fog they passed through.
"It's like we're seeing the shadow of all the baryons," explained Caltech assistant professor Vikram Ravi, using the scientific term for this ordinary matter. "With FRBs as the backlight, we now know roughly where the rest of the matter in the universe is hiding."
The results show about 76 percent of the universe's baryonic matter exists in this intergalactic fog. Meanwhile, 15 percent of the baryonic matter surrounds galaxies in halos and just 9 percent resides inside the galaxies themselves.
This breakthrough was made possible by telescopes like Caltech's Deep Synoptic Array and Australia's Square Kilometre Array Pathfinder, which helped localize the FRBs' origins. Caltech's upcoming DSA-2000 radio telescope, set to detect 10,000 FRBs per year, could be the key to even deeper cosmological insights.
For astronomers, it's a milestone moment—one that brings us closer to understanding not just where we come from, but how the universe is truly structured.
What Astronomers Just Discovered Between Galaxies Changes Everything first appeared on Men's Journal on Jun 17, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
25 minutes ago
- Medscape
‘Popcorn Lung': Making a Historically Difficult Diagnosis
Among the many things that the Industrial Revolution gave rise to was the potential for more rapid spread of public health crises. Communicable diseases such as cholera, typhus, and tuberculosis all spiked during this era due to urbanized living, increased mass communication, and still-evolving sanitation safety measures. The early 20th century also marked increased prevalence of occupational respiratory illnesses, such as silicosis, chronic obstructive pulmonary disease (COPD), and a newly-identified condition — bronchiolitis obliterans — that in many ways has puzzled healthcare professionals ever since. First diagnosed in 1901 among healthy factory workers who were exposed to nitrogen dioxide, this fibrosing obstructive lung disease has earned the moniker 'popcorn lung' because of its connection to an outbreak at a factory 25 years ago. That outbreak in Jasper, Missouri, was among workers who inhaled diacetyl, a synthetic flavoring agent for microwavable popcorn. Although the disease can also be caused by other harmful food production exposures. Characterized by a dry cough, shortness of breath, wheezing, and inflammation that results in partial or complete obliteration of the lung's smallest airways and irreversible scaring, the disease continues to be difficult to diagnose. The disease also is more challenging to care for the longer it goes undetected. While it frequently develops in patients who undergo lung transplant and is associated with rheumatic conditions and various respiratory infections, bronchiolitis obliterans is rare and can masquerade as other common pulmonary diseases when symptoms aren't properly recognized. Difficult Diagnosis In August 2000, employees at Gilster-Mary Lee Corporation, a food manufacturing and distribution company, experienced a similar set of respiratory issues, including cold-like symptoms that didn't improve with medication. The National Institute for Occupational Safety and Health (NIOSH) and the Missouri Department of Health and Senior Services launched an investigation. 'There was this clustering of workers who had developed severe obstructive airway disease and were initially being variously diagnosed with conditions such as emphysema, but, for the most part, they were never smokers,' explained Cecile S. Rose, MD, MPH, a board-certified pulmonology and occupational medicine physician at National Jewish Health, Denver. 'The NIOSH began looking at the workers' epidemiologically and sampling the air. They found that this exposure to diacetyl-containing butter flavoring was the cause. And that's when we began to realize that these types of chemicals, even though they had been stored in very large vats that had lids and were recognized as safe for ingestion, were never safe to be inhaled in large quantities.' The most likely symptoms of 'popcorn lung' are a persistent cough, plus or minus wheezing, and shortness of breath that worsens with physical exertion — none of which are particularly distinctive. 'The typical symptoms are very nonspecific and are not temporally linked to exposure,' said Rose. 'They are insidious. They creep up. And the symptoms don't help you very much in terms of linking the exposure to the risk of lung disease or its symptoms. But sometimes patients will describe upper airway irritation symptoms, such as sore throat, or eye burning.' But there are additional symptoms that can complicate diagnosis. According to Jim Mendez, PhD, CRNP, ANP-BC, clinical associate professor and adult primary care nurse practitioner in the M. Louise Fitzpatrick College of Nursing at Villanova University, Villanova, Pennsylvania, the full spectrum of signs can also include fatigue and chest discomfort. Another troubling indication can be when wheezing is present and does not respond to standard asthma medications, Mendez said. Eric Costanzo, DO, director of Medical Intensive Care and director of the Pulmonary and Critical Care Fellowship Program at Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune City, New Jersey, said that patients will also often experience nonspecific symptoms that can resemble conditions such as asthma or COPD, including exertional dyspnea and low-grade fever. Weight loss may also be seen, he said. 'But the pathology itself can happen for a number of different reasons, just by virtue of the fact that the lungs have only a few ways to respond to injury — and this injury pattern of bronchiolitis obliterans is one of those ways,' said Amy Hajari Case, MD, chief medical officer of the Pulmonary Fibrosis Foundation and director of the Pulmonary Fibrosis Care Center at Piedmont Healthcare in Atlanta. 'There is inflammation and obliteration of the bronchioles, and it's a situation where the inflammation creates airflow obstruction on the smallest level that sets up a clinical picture that we can now recognize.' Functional Testing Can Speed Diagnosis Before a diagnosis can be confirmed, pulmonary function tests are essential to help detect the restricted airflow typical of the condition, suggests Shawn George, DO, an internal medicine physician at Yorktown Health, Vernon Hills, Illinois. 'A computed tomography scan can show damage to the airways, but a biopsy might be needed to confirm the diagnosis.' The disease is more common among patients who undergo bone marrow or lung transplants, a form of chronic allograft rejection, referred to as defined as 'bronchiolitis obliterans syndrome.' According to research conducted by the Cleveland Clinic, approximately 50% of patients who undergo lung transplants will develop bronchiolitis obliterans syndrome within 5 years of surgery while approximately 10% of marrow recipients will develop bronchiolitis obliterans syndrome within 5 years. 'Patients can have this type of lung injury related to some of the transplant immunology that occurs,' said Case. 'It can also happen because of certain types of viral or bacterial infections that set up a more acute situation.' These include respiratory syncytial virus and measles, particularly in children. According to Costanzo, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease-related lung disease can also be triggers. 'Histologically they differ from other lung diseases characterized by concentric fibrosis of the bronchioles and eventual obliteration of the airway lumen,' said Costanzo. Treatment Approaches and Suggestions Quality of life and disease management can be difficult for patients, said Case. 'There isn't a well-defined standard of care practice for how to help people improve their lung function and there isn't extensive data to guide management in this condition. The first thing to do is to halt any culprit exposure to immediately keep the patient from having continued lung damage.' Assuming that can be accomplished, there are a range of over-the-counter and prescription options that Case and other physicians are willing to try for their patients. 'Cough suppressants and inhaled bronchodilators are used for symptom management, as well as oxygen therapy if the patient is hypoxemic,' said Case. 'Pulmonary rehabilitation is also utilized for its various benefits, and other treatments such as macrolide antibiotics, systemic steroids, and immunosuppression are tried on an individual basis. But this is a condition that in many cases doesn't respond well to the things that we do. And so patients do not get that same relief as other patients for which we do have a lot of tools and a lot of evidence for using them, even if that condition is not going to go away, such as COPD.' When it comes to syndrome patients, treatments might also include extracorporeal photopheresis and total lung irradiation. In the worst of all types of cases, patients will require lung transplant. 'One percent of transplants are listed as being for bronchiolitis obliterans for all different etiologies,' said Case. Vagaries of Vaping Another potential cause of bronchiolitis obliterans, but for which more substantial evidence is needed, is use of a vape to inhale nicotine-based chemicals, including those that contain diacetyl. Prior to the COVID-19 pandemic, a rash of e-cigarette or vaping-associated lung injury (EVALI) cases had been seen in hospitals across the country. According to CDC data, more than 2800 hospitalizations and nearly 70 US deaths reported as of February 2020 among people of all ages were attributed to the use of e-cigarettes and vaping products, particularly those containing vitamin E acetate (VEA). 'While the association between vaping and popcorn lung is a concern that has received widespread media attention, it remains less common in clinical practice,' said Dr. Mendez. 'Some flavored e-cigarettes have been found to contain diacetyl; however, there have been very few confirmed cases of bronchiolitis obliterans directly attributable to vaping. What we are seeing more frequently are other vaping-related lung injuries, such as EVALI, which can mimic some of the same respiratory symptoms but represents a different disease process. There is some indication that one of the primary causative agents in EVALI is VEA, although there may be other causes. Continued research and regulation are needed to fully understand the long-term pulmonary risks associated with vaping.' Costanzo said he believes there's a correlation to be concerned about between an increasing prevalence of bronchiolitis obliterans in recent years driven by the popularity of vaping products. Rose is convinced that time will prove a direct causation. 'It might not be as obvious as it was for workers who were exposed to large quantities, but chronic vaping of these chemicals could lead to substantial adverse lung health outcomes in the longer term,' she said. 'The [people] who are vaping regularly might seem fine, but if they're doing that every day for the next 10 years, we might start to see affects. Or they might have more accelerated decline in lung function without having many other symptoms.' Case said she has already seen enough incidences to determine a link. 'For me, the evidence is there,' she said. 'When we talk about vaping-associated lung diseases, bronchiolitis obliterans is one of them.' 'But the problem of lack of clarity is that you can put anything into a vape. Because there is so much variability, it's become more difficult to pin down what can cause this by vaping. There are so many additives to the flavors,' continued Case. 'We need to talk about this as being generally harmful because you lose the weight of evidence when we try to get more specific on something that we just don't have enough information on. And as vaping has become more prevalent, it stands to reason that the people who are more susceptible to lung injury from it will experience it at a higher rate.' Protocols for Better Awareness Greater awareness and suspicion of 'popcorn lung' is needed in the presence of certain symptoms and occupational hazards, experts suggest. 'When a clinician sees signs of emphysema or small airways disease in never smokers, their alarms for work-related or exposure-related lung disease should go up,' said Rose. 'The most important thing is to take a careful occupational history — take the time to ask patients about what they spend their time doing. If they're working in food production or fragrance, that should trigger an understanding that there could be a risk to artificial chemicals or flavorings that can confer risk for lung disease. We're very well-conditioned to taking a careful history for those patients who smoke, but we need the same to be true for vaping now too. We also need to take into account things like hookah or other types of inhalants that may confer risk for small airway diseases.' There's also a significant need to improve awareness of the disease among the general public, especially for those who work in high-risk settings and/or use a vape or similar device. 'The person experiencing it probably doesn't know anyone else who has been diagnosed,' said Case. 'There's not a drug being promoted to treat it. We need to promote self-advocacy and advocacy for loved ones. When our patients are experiencing these symptoms, it's an important message that they need to know. The old medical adage says, 'when you hear hoofbeats think horses, not zebras,' but this is truly one of the zebras. It's being missed.' Case, Costanzo, and Mendez reported no relevant financial disclosures.
CBS News
32 minutes ago
- CBS News
STAAR test results are out. Here's how to look up your student's scores.
Results for the State of Texas Assessments of Academic Readiness exams were released this week, showing improvement in certain areas across the state. Results for math, reading language arts, science and social studies STAAR exams that were taken this spring were released on June 17. Results for exams taken in June will be released on July 31, according to the Texas Education Agency How to look up your student's STAAR test results Log on to and enter your student's unique six-character code, date of birth and legal first name. Your student's unique code should be the same every year. If you don't know your student's code, you can look it up under "Information and Support" and entering their first name and Social Security number. 2025 STAAR test results show slight improvement across Texas Students across Texas continue to show growth in reading, but more than half remain below grade level in math, a concern for long-term academic success, test results show. Despite the positive momentum, some experts remain cautious. "It was really encouraging to see continued growth in reading," said Gabe Grantham, policy advisor for the nonprofit Texas 2036. "But more than half our students are below grade level in math, which is just not okay when we're thinking about how core those skills are for academic and post-academic success."
Yahoo
an hour ago
- Yahoo
PODD Drug Delivery Conference Announces 2025 Keynotes
The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 keynotes NEW YORK, June 18, 2025 /PRNewswire/ -- Today, PODD: Partnership Opportunities in Drug Delivery conference announced the keynotes for its 15th annual conference which takes place on October 27-28 at the Westin Copley Place in Boston, MA. "In presenting a strategic-level program for R&D scientists and business development professionals, the PODD Conference is committed to securing keynotes who demonstrate excellence in science," said Andrew Goldstein, Senior Conference Producer for the PODD Conference. The PODD 2025 keynotes include: MIT's Dr Robert Langer, a pioneer in the research and development of drug delivery technology, will return as the Annual Keynote to discuss the state of innovation in the drug delivery industry. Dr Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor who drove the development of GLP-1 drugs for obesity will present on the liraglutide and semaglutide story, her approach to scientific development and where drug delivery intersects with her R&D work. Patient Keynote Jimi Olaghere will share his journey as a patient with sickle cell disease before and after receiving CASGEVY, a CRISPR-based therapy, and his mission to make these therapies more accessible for patients globally. Dr Mansoor Amiji, University Distinguished Professor, Northwestern University, will join the PODD Conference as the Endogenous Delivery Zeitgeist. Dr Amiji will present on endogenous targeted delivery strategies to overcome biological barriers and improve efficacy and safety. The PODD speaking faculty includes over 100 executives from both the drug development and delivery industries with over 125 session choices including a full afternoon of drug delivery presentations from established to start-up companies. To learn more about the event, visit About the PODD: Partnership Opportunities in Drug Delivery ConferencePharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals, and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations. About the Conference ForumThe Conference Forum is a life science industry research firm that develops conferences, podcasts, newsletters and webinars primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, promoting the exchange of ideas and solutions among peers, and providing high-quality networking. Learn more about the Conference Forum at For media inquiries, contact:Bre Bugbee-Barrettbre@ View original content: SOURCE Partnership Opportunities in Drug Delivery (PODD)
